In premenopausal women, denosumab significantly prevented bone loss and microarchitectural deterioration.
Grace Morrison, PharmD Candidate
Advertisement
Articles by Grace Morrison, PharmD Candidate
Combination treatment of sotorasib plus panitumumab prolongs progression-free survival in those with metastatic colorectal cancer and the KRAS G12C mutation.
Enfortumab vedotin in combination with pembrolizumab showed a manageable safety profile and promising progression free survival and overall survival for locally advanced or metastatic urothelial cancer.
Advertisement
Latest Updated Articles
Enfortumab Vedotin With Pembrolizumab Shows Promise as First-Line Therapy For Those Ineligible for CisplatinPublished: April 17th 2024 | Updated:
Denosumab With Ovarian Function Suppression and Aromatase Inhibitor Therapy in ER-Positive, Early-Stage Breast CancerPublished: May 21st 2025 | Updated:
Advertisement
Advertisement
Trending on Pharmacy Times - Pharmacy Practice News and Expert Insights
1
ACIP Meeting: COVID-19 Vaccines to be Administered Through Shared Clinical Decision-Making
2
ACIP Meeting: Combined MMRV Vaccine, Hepatitis B Vaccine Restricted for Some Age Groups
3
FDA Approves Keytruda Qlex Subcutaneous Injection for Adult and Pediatric Patients With Solid Tumors
4
Intelligent Pharmacy: Leveraging AI and Automation to Enhance Patient Care and Pharmacist Roles
5
